Abstract
Cell therapy may be a potentially attractive approach to restore myocardial contractile performance after an infarction injury. Multipotent stem cells are currently being studied as a possible cell source for myocardial repair within the first few days after the infarction onset in non-revascularizable areas of the left ventricle having viable myocardium. In the presence of fibrotic post-infarction scar with no detectable myocardial viability, direct myocyte precursors, i.e. myoblasts, are being considered as a potential source of new muscle fibres. We review the current clinical experience with transplantation of the autologous skeletal myoblasts in patients with post-infarction heart failure, focusing on percutaneous cell transplantations performed as a sole procedure.
| Original language | English |
|---|---|
| Pages (from-to) | H57-H64 |
| Journal | European Heart Journal, Supplement |
| Volume | 8 |
| Issue number | H |
| DOIs | |
| Publication status | Published - Dec 2006 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Catheter systems
- Cell transplantation
- Heart failure
- Myoblasts
Fingerprint
Dive into the research topics of 'Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver